Mohammad Althubiti
Overview
Explore the profile of Mohammad Althubiti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eid S, Koshak M, Elzubier M, Refaat B, Almaimani R, Althubiti M, et al.
Drug Dev Ind Pharm
. 2025 Feb;
:1-12.
PMID: 39992072
Background: Paracetamol (PAC) overdose causes acute liver injury through oxidative stress, inflammation, and apoptosis. While N-acetyl cysteine (NAC) is the standard treatment, fucoxanthin (FUC), a carotenoid from brown seaweed, has...
2.
El-Readi M, Abdulkarim M, Abdellatif A, Elzubeir M, Refaat B, Althubiti M, et al.
Drug Dev Ind Pharm
. 2024 Jan;
:1-15.
PMID: 38180322
Background: Therapeutic resistance fails cancer treatment. Drug-nanoparticle combinations overcome resistance. Sanguinarine-conjugated nanoparticles may boost sanguinarine's anticancer effects. Methods: Sanguinarine, HPMC-NPs, and doxorubicin were tested on Adriamycin-resistant MCF-7/ADR breast cancer cells,...
3.
Koshak M, El-Readi M, Elzubier M, Refaat B, Adnan Almaimani R, Idris S, et al.
Mar Drugs
. 2023 Nov;
21(11).
PMID: 37999416
Paracetamol or acetaminophen (PAC) is a commonly used analgesic and antipyretic drug. It has been shown that overdoses beyond the therapeutic range can cause hepatotoxicity and acute liver injury. The...
4.
El-Dahmy R, Elsayed I, Hussein J, Althubiti M, Almaimani R, El-Readi M, et al.
Pharmaceutics
. 2023 Apr;
15(4).
PMID: 37111569
Olmesartan medoxomil (OLM) is a first-line antihypertensive drug with low oral bioavailability (28.6%). This study aimed to develop oleogel formulations to decrease OLM side effects and boost its therapeutic efficacy...
5.
Althobaiti B, El-Readi M, Althubiti M, Alhindi Y, Alzahrani A, Al-Ghamdi S, et al.
Front Pediatr
. 2023 Apr;
11:1087095.
PMID: 37009288
Background: Poisoning occurs when a person is exposed to an external substance at a too high dose for them. It is possible for young children to be exposed to chemicals....
6.
Almutairi A, El-Readi M, Althubiti M, Alhindi Y, Ayoub N, Alzahrani A, et al.
Trop Med Infect Dis
. 2023 Feb;
8(2).
PMID: 36828545
(1) Background: Favipiravir (FVP) is a new antiviral drug used to treat COVID-19. It has been authorized to be used in the kingdom of Saudi Arabia in the treatment of...
7.
Babakr A, Mukhtar M, Althubiti M, Al-Amodi H, Almaimani R, Nour Eldin M, et al.
Diabetes Metab Syndr Obes
. 2023 Feb;
16:447-455.
PMID: 36816817
Background: Hyperlipidemia is a common risk factor for atherosclerosis, heart diseases, and other pathological conditions. The factors leading to the oxidation of native low-density lipoproteins remain of valuable importance for...
8.
Hafiz N, El-Readi M, Esheba G, Althubiti M, Ayoub N, Alzahrani A, et al.
Complement Ther Med
. 2023 Jan;
72:102917.
PMID: 36632904
Background: COVID-19 causes moderate to severe illness and is spreading globally. During a pandemic, vitamins and minerals are vital to health. Therefore, the prevalence and epidemiology of supplement use in...
9.
Althubiti M
Saudi J Med Med Sci
. 2022 Oct;
10(3):183-191.
PMID: 36247049
Tyrosine kinase inhibitors (TKIs) have been studied extensively in cancer research, ultimately resulting in the approval of many drugs for cancer therapy. Recent evidence from reported clinical cases and experimental...
10.
Althubiti M
Saudi J Biol Sci
. 2022 Sep;
29(10):103418.
PMID: 36065194
β2M (Beta 2 microglobulin) is a small protein that is found in all nucleated cells, previous finding showed that its levels increased in the serum of the elderly. Buccal cell...